CAJ | 학술논문

目的观察以蛋白酶体抑制剂硼替佐米为主的化疗方案治疗多发性骨髓瘤(MM)的疗效和患者不良反应.方法 28例MM患者接受以硼替佐米为主的联合方案化疗.疗效评定按照EBMT标准进行.结果 28例MM患者中,初治20例,复发难治8例.25例可评估疗效,总反应率达100％(25/25),其中完全缓解(CR)5例,接近完全缓解(nCR) 10例,部分缓解(PR)10例.主要不良反应包括周围神经病变、血小板减少、消化道反应及病毒感染,经对症处理后好转,一般不影响治疗.结论以硼替佐米为主的联合化疗治疗初治和复发难治MM起效较快,治疗反应率高,不良反应可耐受.
목적 관찰이단백매체억제제붕체좌미위주적화료방안치료다발성골수류(MM)적료효화환자불량반응.방법 28례MM환자접수이붕체좌미위주적연합방안화료.료효평정안조EBMT표준진행.결과 28례MM환자중,초치20례,복발난치8례.25례가평고료효,총반응솔체100％(25/25),기중완전완해(CR)5례,접근완전완해(nCR) 10례,부분완해(PR)10례.주요불량반응포괄주위신경병변、혈소판감소、소화도반응급병독감염,경대증처리후호전,일반불영향치료.결론 이붕체좌미위주적연합화료치료초치화복발난치MM기효교쾌,치료반응솔고,불량반응가내수.
Objective To examine the efficacy and adverse reactions of bortezomib-based chemotherapy in treatment of multiple myeloma (MM).Methods Twenty-eight patients with multiple myeloma received a joint chemotherapy containing bortezomib.The efficacy was determined according to EBMT criteria.Results 28 patients received the chemotherapy,20 patients were newly diagnosed and 8 patients were relapsed or refractory.25 patients can be evaluateed efficacy.The total response rate was 100 ％ (25/25),consisting of 5 patients with complete response (CR),10 patients with almost complete remission (nCR),10 patients with partial remission (PR).The main side effects include peripheral neuropathy,thrombocytopenia,gastrointestinal disorders and viral infections.These side effects were improved by symptomatic treatment and generally did not affect the treatment.Conclusion For the newly diagnosed and relapsed or refractory multiple myeloma cases,bortezomib-based chemotherapy is a safe and effective therapeutic drug with rapid onset,high treatment response rate,and adverse reaction can be tolerated.